Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Study in 3 Parts to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of MIV-818 in Patients With Liver Cancer Manifestations

NCT03781934 is registered in ClinicalTrials.gov with Medivir as lead sponsor.

NCT NCT03781934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03781934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Study in 3 Parts to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of MIV-818 in Patients With Liver Cancer Manifestations
Lead sponsor
Medivir
Phase
Phase 1/2
Overall status
Completed
Start date
September 5, 2018
Completion date
June 16, 2025
Enrollment
53 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, intrahepatic cholangiocarcinoma, liver metastases